Merit E. Cudkowicz, Md
Clinical trials sponsored by Merit E. Cudkowicz, Md, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Massive ALS trial tests multiple drugs at once to find a way to slow the deadly disease Results expected Jul 2027 (estimated)
- New ALS drug trial hopes to slow disease progression Results expected Jul 2027 (estimated)
-
New drug DNL343 tested in major ALS trial – hope for slowing disease?
Disease control CompletedThis study tested a drug called DNL343 in 249 people with ALS, a serious nerve disease that weakens muscles over time. The goal was to see if DNL343 could slow the disease and help people live longer. The trial used a flexible platform design to test multiple treatments at once.
Phase 2/3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could this daily pill slow ALS?
Disease control CompletedThis completed Phase 2/3 trial tested an oral drug called ABBV-CLS-7262 in 310 people with ALS. Participants took the drug or a placebo once daily for 24 weeks. The study measured how fast the disease progressed and survival rates. The goal was to see if the drug could slow ALS a…
Phase 2/3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC